Precision medicine for cancer treatment has rapidly evolved in the last three decades from non-specific cytotoxic chemotherapy to very specific targeted therapies which has resulted in unprecedented improvement in survival for a variety of cancers. In personalised cancer medicine, tumour genetics is used for optimal drug selection (‘right drug’). However, no strategy is used for personalised dose selection (‘right amount’), particularly with kinase inhibitors (KIs), the largest class of targeted therapies for cancer treatment. These drugs have reformed cancer treatment with superior survival outcomes over traditional chemotherapies, however, a ‘one-size fits-all’ starting dose is prescribed ignoring any individual patient differences. Such fixed doses are usually determined in small clinical trials, and patients with co-medications/morbidities, and the elderly and the very ill, are often excluded, and only represents 5% of the real-world cancer population. It is well-known that when this one-size fits-all dosing strategy is applied to cancer patients in the community, a large variability in clinical outcomes (responses/toxicities/survival) are observed. A significant proportion of cancer patients experience toxicity and therapeutic failure, leading to poor patient outcome (early progression and severe toxicity) and significant health and economic burden. Our team has successfully implemented a state-wide clinical program that enables oncologists to provide individualised dosing for their patients to help minimise the toxicity and maximise the efficacy. By assembling a multi-interdisciplinary team consisting of clinicians, clinical pharmacologists, pharmacists, health services, and digital teams — and showing timely coordination and shared commitment, we can now make personalised cancer care a reality for Australians. Identifying the limiting barriers and facilitators of changing clinical practice was key to our implementation success.